ArticleSensors (Basel, Switzerland)2026
An Advanced 3D Model of Vascularized Epithelial Ovarian Cancer in a Tumor-on-a-Chip System Based on Multi-Cell Culture.
Article in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Epithelial ovarian cancer (EOC) is a highly lethal malignancy characterized by significant heterogeneity and poor prognosis due to late-stage diagnosis and chemotherapy resistance. Traditional two-dimensional (2D) models fail to replicate the complexity of the tumor microenvironment (TME), necessitating the development of advanced in vitro systems. Here, we present a novel microfluidic tumor-on-a-chip (ToC) system that accurately models key features of EOC, including heterogeneity and vascularization. The developed cellular model was evaluated for functionality. It was demonstrated that endothelial cells of blood vessels within a collagen matrix successfully migrated toward the cancerous tissue, while the multicellular and multilayered tumor construct secreted pro-angiogenic factors. Additionally, long-term culture conditions induced inflammatory responses, mimicking in vivo tumor progression. This innovative platform enables precise investigations into EOC biology, angiogenesis, and TME interactions. Furthermore, it holds significant potential for drug screening, assessing therapeutic efficacy, and advancing personalized oncology approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.